 
|
CLINICAL TRIALS PMP Cure Research Appendix Cancer Research Colorectal Cancer Research Donate to Research Gastric Cancer Research Mesothelioma Research Mesothelioma Research Peritoneal Carcinomatosis Research Peritoneal Surface Malignancy Research Pseudomyxoma Peritonei Research Research Funding Sources Here are listings of research studies and clinical trials taking place around the world for the treatment of Colorectal Cancers, Gastric Cancers, Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis, Mucinous Adenocarincoma and Appendix cancer, in general. New research studies and clinical trials for the treatment of Colorectal Cancers, Gastric Cancer, Mesothelioma, Ovarian Cancer, Panceatic Cancer, Pseudomyxoma Peritonei, Appendix Cancer and Peritoneal Carcinomatosis are posted here as they become available. Mesothelioma: laboratory and animal research programs are in progress to determine the cause(s) of short and long term outcomes between male and female patients. International Peritoneal Mesothelioma data base, contact: Dr Tristan Yan Financial contributions can be donated to the: Peritonectomy Foundation which is part of our University Foundation and is tax deductible in Australia. For more information, contact: Professor David L Morris
Professor Pompiliu Piso, in Regensburg, Germany provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis. Tel.:0941-944-6809
UNITED STATES of AMERICA via postal mail University of Pittsburgh Cancer Institute Development, via telephone/credit card (412)623-4700 or Laura A. Lambert, M.D.
Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IC) are considered the standard of care for patients with peritoneal dissemination of appendiceal cancer, ovarian cancer and peritoneal mesothelioma. Data are also accumulating that show a survival advantage for this approach in selected patients with carcinomatosis for colorectal cancer. However, there is no consensus as to the optimal form of IC. Usage of a wide variety of chemotherapy agents, in various carrier solutions, administered either with or without hyperthermia, for a broad range of times (30 minutes to days), has been reported with remarkably comparable rates of success. Consequently, the optimal form of IC is unknown, while on the other hand, clinically significant systemic side effects are well-documented. The main goal of this project is to investigate alternative peritoneal perfusion techniques that result in tumor –specific cell death with less systemic toxicity. Identification of tumor-specific cytotoxic peritoneal perfusates will improve oncologic outcomes combined with decreased toxicity for patients undergoing CRS and HIPEC.
Because non-carcinoid appendical cancers are extremely rare, little is known about the genetic pathways that are involved in the growth and dissemination of these tumors. The purpose of this research project is to investigate the genetic and protein expression profiles of non-carcinoid appendiceal cancers. The potential benefits of this project are to identify novel targets for therapy, provide better prognostic information, and identify people at risk for developing appendiceal cancer based upon genetic and protein profiles.
Patients with peritoneal ascites often suffer debilitating symptoms including life-threatening anorexia and cachexia. Symptom management is challenging and often inadequate, resulting in loss of quality of life (QoL). This study is investigating the cytokine and other protein profiles of malignant and non-malignant ascites for potential targets for palliation. This is an on-going prospective, observational study at the UMass Memorial Medical Center. Patients with ascites retrieved either at surgery or by paracentesis are asked to complete a brief QoL questionnaire. Relative intensity of cytokine and protein expression in the ascites fluid is quantified. Significant differences between non-malignant and malignant ascites are determined and correlated with QoL data. Through this study we hope to identify targets for more effective palliation of symptomatic ascites. So far we have identified angiogenin as a potential target for anti-angiogenic therapy in malignant ascites. In addition, the appetite suppressant, leptin, may be a potential target for palliation of ascites-related anorexia. Donations for Dr Lambert's research can be sent via: 1. research into quality of life following the HIPEC procedures. 2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease. 3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis. For more information, in general call 336 716 4276, EST. The Cancer Biology program at the Creighton University School of Medicine is directed by Dr. Brian Loggie, professor of surgery, and chief of the division of surgical oncology. He has created a translational working group (TWG) consisting of surgical oncologists, pathologists and basic scientists working collaboratively on several projects relating to Pseudomyxoma Peritonei cure research. The TWG has begun research identifying mutations in multiple target genes. They are categorizing the mutations on the basis of known signaling pathways in order to combine this knowledge with known pathologic variables and patient outcome. With new biologic insights, it will be possible to consider new approaches to clinical strategies and laboratory testing for PMP patients. The TWG has worked successfully together. The TWG has previously been successful in identifying novel mutations in the epidermal growth factor (EGFR) gene in Mesothelioma, identifying the biologic implications, confirming the mutation effects on cell signaling function in the laboratory, and devising new treatment strategies. The TWG seeks to develop information which correlates with prognosis, which aids in developing new treatments, and may guide treatment selection for various presentations and forms of PMP. The TWG is also continuing to focus on the biology of mucin (specific types of which are generated by PMP tumors), particularly when it is blocked or down-regulated. Our research is showing that if we block mucin production, we can influence PMP tumor cell growth, and even arrest development of these cells. The development of this knowledge will expand treatments for Pseudomyxoma Peritonei patients. Related website: http://medschool.creighton.edu/medicine/centers/cancer/res/studies/index.php Contact person to be notified for patient participation in the program:
The Foundation for Applied Research in Gastrointestinal Oncology (FARGO) is a non-profit 501 (c)(3) organization that promotes research, education and patient care in gastrointestinal oncology. FARGO's primary objective is to facilitate the transfer of basic science research into innovations in patient care. The responsibilities of FARGO include financial support, administrative support, and space for continued progress in the prevention and treatment of gastrointestinal cancer. Donations to FARGO are tax deductible and can be made to: FARGO Herbert J. Zeh, III, MD INTERNATIONAL ASCO reviews NEW clinical trials for GI and Colon cancers Source: ASCO 2009 International Cancer Genome Consortium UNC Center for Functional GI and Motility Disorders Research studies for GI and Motility Disorders Source: UNC 2009 Vanderbilt Clinic COLORECTAL CANCERS Clinical Trials for Colorectal Cancers at Vanderbilt Clinic Additional Services and Studies Merck Clinical Study MK2206 recruiting patients w/locally advanced or metastatic solid tumors Source: Merck, 2009 CenterWatch Clinical Trials Listing Service Free subscription Research Gate Data Base Free subscription United States Military Cancer Institute Gene Therapy Leukocyte Therapy for Patients with Unresectable Cancer http://clinicaltrials.gov/ct2/show/NCT00607802?term=cui&rank=5 White Blood Cell Transfer for Patients with Unresectable Cancer http://www.cancer.gov/clinicaltrials/CCCWFU-99107 Granulocyte Research http://munogenics.com Aspirin Use for Chemoprotection of Colorectal Adenoma Cancers Source: Journal of the National Cancer Institute, June 2009 Results of Phase III Systemic Chemotherapy Trial for Advanced Gastric Cancer Source: Annals of Oncology, July 2009 Pseudomyxoma Peritonei Click here to read more about Pseudomyxoma Peritonei This page has been contributed by the family, friends and colleagues of Marcus "Dwain" Reynolds. Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours. The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications. We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates. Individuals or organizations who plagiarize this copyrighted website will be prosecuted. |
  |
